Investing.com -- Evaxion Biotech AS (NASDAQ:EVAX) stock rose 4.2% in Monday’s premarket trading following the company’s presentation of promising preclinical data for its acute myeloid leukemia (AML) vaccine candidate at a major medical conference.
The clinical-stage TechBio company revealed that its EVX-04 vaccine triggered strong T-cell responses and effectively prevented tumor growth in preclinical models. These findings were presented at the American Society of Hematology Annual Meeting in Orlando, Florida.
EVX-04 is an off-the-shelf therapeutic cancer vaccine developed using Evaxion’s proprietary AI-Immunology platform. The vaccine targets multiple non-conventional endogenous retrovirus (ERV) tumor antigens that are expressed in cancer cells but absent in normal tissue.
"AML is characterized by high mortality rates and massive unmet medical need as current treatment options are limited and often insufficient," said Birgitte Rønø, CSO of Evaxion. "The new data confirms our belief that EVX-04 could significantly improve treatment options for AML patients."
According to the company, its AI platform identified five million ERV antigen fragments from AML patient sequencing data, ultimately selecting 16 optimal ERV fragments based on cross-patient relevance and immunogenic potential. The new data confirms that all 16 fragments elicit specific immune responses.
Evaxion believes this approach could be applicable to other hard-to-treat cancers where immunotherapies remain inadequate and conserved immunogenic antigens can be identified.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.








